We benchmarked these results to the effect of Apc−/−Pkd1−/− versus Apc−/− organoids treated with the WNT pathway inhibitor PRI-724 [54], which inhibits the interaction between CTNNB1 and its transcriptional coactivator CBP, and should be active in all CRC arising from an Apc−/− genotype. This evidence concerns the gene APC and colorectal carcinoma.